TRT Jatenzo denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Jatenzo as Duplicate Therapy

Aetna's duplicate-therapy denial on Jatenzo (testosterone undecanoate, an oral testosterone capsule) means the plan has identified that another testosterone product is already active on your profile — typically a different formulation such as an injectable, a topical gel, or a patch. Aetna's utilization-management logic flags concurrent testosterone prescriptions as therapeutically duplicative and will not pay for both. This denial is fully appealable, and the path forward depends on whether the duplication is real or a documentation artifact.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial. Aetna must respond within 30 days for standard appeals and 72 hours for expedited.
• External review: After a final internal denial, escalate to an independent review organization within approximately four months. The IRO's decision is binding on the plan.
• Expedited track: Request expedited review if the denial leaves you without adequate treatment.

## Two Appeal Paths Depending on Your Situation

Path A — True transition (switching formulations): If Jatenzo is intended to replace a prior testosterone product, the appeal should confirm that the prior product is being discontinued and that Jatenzo is the new ongoing therapy. Include documentation from the prescriber confirming the transition, the clinical reason for the formulation switch (e.g., oral route preference, tolerability, adherence considerations), and confirmation that the prior prescription will not be refilled concurrently.

Path B — Documentation error: If no other testosterone product is actively being used, the duplication flag is a data error. Obtain a letter from the dispensing pharmacy confirming no concurrent fill, and have your prescriber confirm in writing that Jatenzo is the sole testosterone product prescribed.

## What to Gather

1. Prescriber letter — explains the clinical rationale for Jatenzo specifically (oral route, patient-specific factors per the FDA-approved prescribing information), confirms the treatment plan, and addresses the duplication concern directly. 2. Pharmacy records — showing current and recent testosterone-product dispensing history to clarify whether a concurrent fill exists. 3. Transition documentation (Path A) — office note confirming discontinuation of prior formulation and reasons for the switch. 4. Denial details — identify which product Aetna flagged as the duplicate; tailor the rebuttal to that specific product. 5. FDA label for Jatenzo — the prescriber's letter should reference the approved indication and the clinical basis for selecting this oral formulation.

## Criteria-Mapping Structure

Obtain Aetna's published duplicate-therapy and testosterone coverage policy. Respond to each criterion:

| Aetna Criterion | Your Evidence | |---|---| | No concurrent active testosterone prescription | Pharmacy records, prescriber confirmation | | Clinical rationale for this specific formulation | Prescriber letter, FDA label reference | | Transition plan or sole-agent confirmation | Office note or prescriber letter |